←Back to Expert Scholars
Translational Medicine / 转化医学HER2 Ultra-Low
Shanu Modi
MD
🏢Memorial Sloan Kettering Cancer Center🌐USA
Attending Physician, Breast Medicine Service
58
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Shanu Modi led the DESTINY-Breast04 and DESTINY-Breast06 trials that established trastuzumab deruxtecan in HER2-low and HER2-ultralow breast cancer. Her work redefined HER2 as a continuum of therapeutic targets. She continues to lead practice-changing ADC trials at MSKCC.
Share:
🧪Research Fields 研究领域
Trastuzumab deruxtecan
DESTINY-Breast trials
HER2 biology
ADCs
Metastatic breast cancer
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Shanu Modi 的研究动态
Follow Shanu Modi's research updates
留下邮箱，当我们发布与 Shanu Modi（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment